Skip to main content
. 2013 Jun 16;15(6):577–589. doi: 10.1007/s10198-013-0495-y

Fig. 4.

Fig. 4

Evaluation of negative patient-relevant outcomes by G-BA in the included EBAs. For products at the end of the arrows this evaluation leads to an up- and downgrade, respectively. This evaluation does not influence the benefit level of the products before the gap